Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
Pacira BioSciences reported record revenue and gross margins in 2025, with continued strong performance into early 2026 across its non-opioid pain management products. The company emphasizes execution of its strategic 5x30 plan driving shareholder value, including a $300 million share repurchase program and a favorable patent litigation settlement …